“Diabesity: the true epidemic of the XXI century” & “Raynaud’s Phenomenon”

Rodolfo J. Galindo, MD, FACE
Associate Professor of Clinical Medicine
University of Miami Miller School of Medicine 

Dr. Rodolfo J. Galindo graduated from the Institute of Medical Sciences at the University of Havana in 2005. Dr. Galindo completed his Internal Medicine residency and Endocrinology fellowship at the Albert Einstein College of Medicine, and North Shore University Hospital, in New York. After completing his fellowship, Dr. Galindo joined the faculty, as an Assistant Professor, of the Mount Sinai School of Medicine, where he was the Director of the Inpatient Diabetes Service. In 2017, Dr. Galindo joined the faculty of Emory University, to work with his mentor, Dr. Guillermo E. Umpierrez, on clinical investigation in diabetes and obesity. Currently, Dr. Galindo is currently an Associate Professor of Medicine at the University of Miami, and Director of the Comprehensive Diabetes Center of UHealth and the Director of Diabetes Management for Jackson Health System, in Miami.

His clinical and research areas of interest included management of diabetes, obesity and CKD, using diabetes technology. His research program is supported by the NIH, NIDDK, foundations and industry. Dr. Galindo had over 120 publications peer-reviewed manuscripts, abstracts and book chapters. His works has been published in high-impact journals, including Endocrine Reviews, Diabetes Care, JAMA, BMJ Open Diabetes Care, Diabetes Research and Clinical Practice, Endocrine Practice, Journal of Clinical Endocrinology and Metabolism, Diabetes, Obesity & Metabolism, Obesity, Journal of Diabetes Science and Technology, Journal of the American Surgical Society, etc. Dr. Galindo has also served as member and author of national and international diabetes guidelines, including the Consensus Statement on the Use of Diabetes Technology in the Hospital (sponsored by the Diabetes Technology Society in 2020), the AACE Diabetes Mellitus Comprehensive Care Plan in 2022 and AACE Algorithm for the Management of Type 2 Diabetes in 2023 (sponsored by the American Association of Clinical Endocrinologists). Dr. Galindo is currently a member of the taskforce to update the Diabetes Ketoacidosis guidelines (sponsored by the American Diabetes Association, 2023-2024), and also a member/writing author of the Standard of Care for Diabetes guidelines from ADA 2024.

Eric Greidinger, MD
Associate Professor of Medicine
University of Miami Miller School of Medicine 

Dr. Eric Greidinger is an Associate Professor of Medicine and Microbiology & Immunology at the University of Miami Miller School of Medicine and Staff Physician in Rheumatology at the Miami VA. He received his MD and completed an Internal Medicine residency at the University of Michigan and Rheumatology fellowship at Johns Hopkins. Dr. Greidinger joined the University of Miami faculty in 2004 and was Chief of the Division of Rheumatology for 10 years starting in 2009. His research interests include anti-RNP autoimmunity, innate immunity in autoimmune diseases, and the topic for today’s talk, Raynaud’s Phenomenon.

_______________________________________________________________________________________________________________________________________________________________________________________________

Join Meeting!

Dr. Galindo’s OBJECTIVES:

• Demonstrate understanding of the prevalence of diabetes and obesity
• Evaluate patients with diabetes and obesity
• Provide evidence-based medical care of patients with diabetes and obesity

Dr. Greidinger’s OBJECTIVES:

• Distinguish Raynaud’s Phenomenon
• Differentiate primary and secondary Raynaud’s
• Examine observations regarding the immunopathogenesis of secondary Raynaud’s

FACULTY DISCLOSURES:

Dr. Galindo has indicated that he has no relevant financial relationships with commercial interests.

Financial Relationship                                     Commercial Interest/Organization
Contractor                                                      Dexcom, Novo Nordisk, Eli Lilly
Consultant                                                      Abbott, Aztra Zeneca, Bayer, Boehringher, Dexcom, Eli Lilly, Medtronic, Novo Nordisk
Royalties/Patent Beneficiary                            UpToDate, ClinicalKey

Dr. Greidinger has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                     Commercial Interest/Organization
Contractor                                                      Horizon Pharmaceutical, Mitsubishi Tanabe Pharma, Eli Lilly

PLANNING COMMITTEE DISCLOSURE:

Dr. Deshpande has indicated that he has no relevant financial relationships with commercial interests.

Dr. Weiss has indicated the following relevant financial relationships with commercial interests:
Financial Relationship                                     Commercial Interest/Organization
Consultant/Contractor                                       Prizm LLC

All the relevant financial relationships for these individuals have been mitigated.

TARGET AUDIENCE:
Primary care physicians.

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.